Patents Assigned to Vascular Biogenics Ltd.
-
Publication number: 20160143968Abstract: The invention provides methods of reducing or decreasing a size of a tumor or eliminating a tumor by inhibiting, decreasing, or reducing neo-vascularization or angiogenesis in a tumor in a patient by administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter. Also provided is a homogeneous population of an adenovirus comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and its uses thereof.Type: ApplicationFiled: November 23, 2015Publication date: May 26, 2016Applicant: Vascular Biogenics Ltd.Inventors: Eyal BREITBART, Andrea Leubitz, Erez Feige
-
Publication number: 20160121001Abstract: The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.Type: ApplicationFiled: February 4, 2014Publication date: May 5, 2016Applicant: Vascular Biogenics Ltd.Inventors: Andrea Rachel LEUBITZ, Naamit SHER, Erez FEIGE, Eyal BREITBART
-
Patent number: 9254297Abstract: The current disclosure provides pharmaceutical compositions containing an oxidized phospholipid, such as 1-hexadecyl-2-(4?-carboxybutyl)-glycero-3-phosphocholine (VB-201) and a thermosoftening carrier, e.g., a poloxamer. The pharmaceutical compositions may further comprise an anti-adherent agent, such as talc and/or a thixotropic agent. The current disclosure further provides processes for preparing the pharmaceutical compositions. The disclosure further provides capsules containing the pharmaceutical compositions. Uses of such pharmaceutical compositions and capsules in treating inflammatory disorders are also disclosed.Type: GrantFiled: March 11, 2013Date of Patent: February 9, 2016Assignee: Vascular Biogenics Ltd.Inventors: Naamit Sher, Victor M. Young, Alyn McNaughton, Massoud Bakhshaee, Ian Robert Wilding
-
Patent number: 9206206Abstract: Novel oxidized lipids are provided herein, as well as methods for producing same, and uses thereof in treating or preventing an inflammation associated with endogenous oxidized lipids and related conditions.Type: GrantFiled: November 5, 2009Date of Patent: December 8, 2015Assignee: Vascular Biogenics Ltd.Inventors: Eti Kovalevski-Ishai, Zeev Ziniuk, Gideon Halperin, Itzhak Mendel, Erez Feige, Niva Yacov, Eyal Breitbart
-
Patent number: 9200056Abstract: The invention provides methods of reducing or decreasing a size of a tumor or eliminating a tumor or inhibiting, decreasing, or reducing neo-vascularization or angiogenesis in a tumor in a patient by administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter. Also provided is a homogeneous population of an adenovirus comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and its uses thereof.Type: GrantFiled: October 29, 2014Date of Patent: December 1, 2015Assignee: Vascular Biogenics Ltd.Inventors: Eyal Breitbart, Andrea Leubitz, Erez Feige, Richard Penson
-
Patent number: 9006217Abstract: Novel synthetic routes, which are highly applicable for industrial preparation of therapeutically beneficial oxidized phospholipids, are disclosed. Particularly, novel methods for efficiently preparing compounds having a glycerolic backbone and one or more oxidized moieties attached to the glycerolic backbone, which are devoid of column chromatography are disclosed. Further disclosed are novel methods of introducing phosphorus-containing moieties such as phosphate moieties to compounds having glycerolic backbone and intermediates formed thereby. Further disclosed is substantially pure 1-hexadecyl-2-(4?-carboxy)butyl-sn-glycero-3-phosphocholine (CI-201).Type: GrantFiled: March 15, 2013Date of Patent: April 14, 2015Assignee: Vascular Biogenics Ltd.Inventors: Gideon Halperin, Eti Kovalevski-Ishai
-
Patent number: 8999960Abstract: Novel oxidized thiophospholipids are provided herein, as well as methods for producing same, and uses thereof in treating or preventing an inflammation associated with endogenous oxidized lipids and related conditions. Exemplary oxidized thiophospholipid according to embodiments described herein have the formula: wherein X1, X2, A1, A2, B?, B?, D? and D? are as described herein.Type: GrantFiled: October 1, 2009Date of Patent: April 7, 2015Assignee: Vascular Biogenics Ltd.Inventors: Eyal Breitbart, Eti Kovalevski-Ishai, Erez Feige, Itzhak Mendel, Zeev Ziniuk, Gideon Halperin
-
Publication number: 20150044280Abstract: The invention provides methods of reducing or decreasing a size of a tumor or eliminating a tumor or inhibiting, decreasing, or reducing neo-vascularization or angiogenesis in a tumor in a patient by administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter. Also provided is a homogeneous population of an adenovirus comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and its uses thereof.Type: ApplicationFiled: October 29, 2014Publication date: February 12, 2015Applicant: Vascular Biogenics Ltd.Inventors: Eyal BREITBART, Andrea Leubitz, Erez Feige, Richard Penson
-
Patent number: 8916378Abstract: A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided. The nucleic acid construct includes: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of an apoptosis signaling molecule; and (b) a second polynucleotide region encoding a cis acting regulatory element being for directing expression of the chimeric polypeptide in a specific tissue or cell; wherein the ligand binding domain is selected such that it is capable of binding a ligand present in the specific tissue or cell, whereas binding of the ligand to the ligand binding domain activates the effector domain of the apoptosis signaling molecule. Also provided are methods of utilizing this nucleic acid construct for treating diseases characterized by excessive or aberrant neo-vascularization or cell growth.Type: GrantFiled: March 5, 2013Date of Patent: December 23, 2014Assignee: Vascular Biogenics Ltd.Inventors: Dror Harats, Shoshana Greenberger, Eyal Breitbart
-
Patent number: 8859745Abstract: An isolated polynucleotide functional as a promoter in eukaryotic cells is disclosed. The isolated polynucleotide includes an endothelial specific enhancer element as detailed herein. Further disclosed is a method of expressing a nucleic acid sequence of interest in endothelial cells.Type: GrantFiled: June 3, 2009Date of Patent: October 14, 2014Assignee: Vascular Biogenics Ltd.Inventors: Dror Harats, Eyal Breitbart, Nira Bloom
-
Patent number: 8859747Abstract: An isolated polynucleotide functional as a promoter in eukaryotic cells is disclosed. The isolated polynucleotide includes an endothelial specific enhancer element as detailed herein. Further disclosed is a method of expressing a nucleic acid sequence of interest in endothelial cells.Type: GrantFiled: March 13, 2013Date of Patent: October 14, 2014Assignee: Vascular Biogenics Ltd.Inventors: Dror Harats, Eyal Breitbart, Nira Bloom
-
Patent number: 8846401Abstract: An isolated polynucleotide functional as a promoter in eukaryotic cells is disclosed. The isolated polynucleotide includes an endothelial specific enhancer element as detailed herein. Further disclosed is a method of expressing a nucleic acid sequence of interest in endothelial cells.Type: GrantFiled: April 24, 2012Date of Patent: September 30, 2014Assignee: Vascular Biogenics Ltd.Inventors: Dror Harats, Eyal Breitbart, Nira Bloom
-
Patent number: 8835398Abstract: Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.Type: GrantFiled: July 13, 2012Date of Patent: September 16, 2014Assignee: Vascular Biogenics Ltd.Inventors: Dror Harats, Shoshana Greenberger, Eyal Breitbart, Livnat Bangio, Michael Peled
-
Patent number: 8802875Abstract: Novel synthetic routes, which are highly applicable for industrial preparation of therapeutically beneficial oxidized phospholipids are disclosed. Particularly, novel methods for efficiently preparing compounds having a glycerolic backbone and one or more oxidized moieties attached to the glycerolic backbone, which are devoid of column chromatography are disclosed. Further disclosed are novel methods of introducing phosphorous-containing moieties such as phosphate moieties to compounds having glycerolic backbone and intermediates formed thereby.Type: GrantFiled: December 10, 2012Date of Patent: August 12, 2014Assignee: Vascular Biogenics Ltd.Inventors: Gideon Halperin, Eti Kovalevski-Ishai
-
Patent number: 8759557Abstract: Novel synthetic routes, which are highly applicable for industrial preparation of therapeutically beneficial oxidized phospholipids are disclosed. Particularly, novel methods for efficiently preparing compounds having a glycerolic backbone and one or more oxidized moieties attached to the glycerolic backbone, which are devoid of column chromatography are disclosed. Further disclosed are novel methods of introducing phosphorous-containing moieties such as phosphate moieties to compounds having glycerolic backbone and intermediates formed thereby.Type: GrantFiled: March 12, 2013Date of Patent: June 24, 2014Assignee: Vascular Biogenics Ltd.Inventors: Gideon Halperin, Eti Kovalevski-Ishai
-
Publication number: 20140155467Abstract: Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.Type: ApplicationFiled: October 21, 2013Publication date: June 5, 2014Applicant: VASCULAR BIOGENICS LTD.Inventors: Dror HARATS, Shoshana GREENBERGER, Eyal BREITBART, Livnat BANGIO, Michael PELED
-
Patent number: 8569529Abstract: Novel synthetic routes, which are highly applicable for industrial preparation of therapeutically beneficial oxidized phospholipids are disclosed. Particularly, novel methods for efficiently preparing compounds having a glycerolic backbone and one or more oxidized moieties attached to the glycerolic backbone, which are devoid of column chromatography are disclosed. Further disclosed are novel methods of introducing phosphorus-containing moieties such as phosphate moieties to compounds having glycerolic backbone and intermediates formed thereby. Further disclosed is substantially pure 1-hexadecyl-2-(4?-carboxy)butyl-sn-glycero-3-phosphocholine (CI-201).Type: GrantFiled: November 9, 2012Date of Patent: October 29, 2013Assignee: Vascular Biogenics Ltd.Inventors: Gideon Halperin, Eti Kovalevski-Ishai
-
Patent number: 8563534Abstract: Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided.Type: GrantFiled: March 27, 2012Date of Patent: October 22, 2013Assignee: Vascular Biogenics Ltd.Inventors: Dror Harats, Jacob George, Gideon Halperin, Niva Yacov, Eti Kovalevski-Ishai
-
Publication number: 20130237720Abstract: Novel synthetic routes, which are highly applicable for industrial preparation of therapeutically beneficial oxidized phospholipids, are disclosed. Particularly, novel methods for efficiently preparing compounds having a glycerolic backbone and one or more oxidized moieties attached to the glycerolic backbone, which are devoid of column chromatography are disclosed. Further disclosed are novel methods of introducing phosphorus-containing moieties such as phosphate moieties to compounds having glycerolic backbone and intermediates formed thereby. Further disclosed is substantially pure 1-hexadecyl-2-(4?-carboxy)butyl-sn-glycero-3-phosphocholine (CI-201).Type: ApplicationFiled: March 15, 2013Publication date: September 12, 2013Applicant: Vascular Biogenics Ltd.Inventors: Gideon Halperin, Eti Kovalevski-Ishai
-
Publication number: 20130225525Abstract: Methods of treatment which utilize co-administration of the oxidized lipid VB-201 with an additional therapeutically active agent are described herein. Methods of treating a cardiovascular disease are described herein, comprising co-administration of VB-201 and a statin to a subject who is not fully responsive to the statin, as well as methods of treating an inflammatory disease or disorder, comprising co-administration of VB-201 and glatiramer acetate. A pharmaceutical composition comprising VB-201, identified for use in combination with glatiramer acetate, is also described herein. Methods of determining a therapeutically effective amount of VB-201 in a subject and of determining a therapeutically effective amount of VB-201 for co-administration with an additional therapeutically active agent are also described. Novel unit dosage forms of VB-201 and methods utilizing same are also disclosed.Type: ApplicationFiled: March 14, 2013Publication date: August 29, 2013Applicant: Vascular Biogenics Ltd.Inventor: Vascular Biogenics Ltd.